Post-Radiation Chemo in Patients w/Newly Diagnosed Ependymoma

Phase III randomized trial of post radiation chemotherapy in patients with newly diagnosed Ependymoma ages 1 to 21 years.

November 22, 2017

  • Clinical Trial Information

    Trial Contact: Boettger, Sadie; El-Shami, Jessica; Francois, Laetitia Claire; Spinelli, Jennifer

  • IRB No: ACNS0831

    Protocol Abbrev: ACNS0831

    Principal Investigator: Vincent F. Giusti, MD

    Sub Investigators: AguilarBonilla, Ana MD; Eslin, Don MD; Martin, Rebecca, ARNP; Pope, Michele ARNP; Smith, Amy MD; Story, Allison ARNP; Sullivan Darden, Kelly ARNP; Sutphin, Robert MD; Wieber, Laura ARNP; Levy, Alejandro MD

    Phase: Drug: Phase III

    Age Group: Pediatric

    Secondary Protocol No: ACNS0831

    Treatment: Drug Therapy, Radiation, Correlative Biology Study

    Conditions: Brain

    Therapies Involved: Chemotherapy ID: NCT01096368

  • Objective

    A trial is studying chemotherapy to see how well it works compared to observation chemotherapy and radiation therapy in treating young patients with ependymoma.

  • Key Eligibility

    Ages Eligible for Study: 1 Year to 21 Years; Genders Eligible for Study: Both; Accepts Healthy Volunteers: No